Arthur Snyder, MD
Rheumatology · Las Cruces, NMNPI 1629079710
Payments from drug & device makers
Across 770 payments — averaging $1962.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$910K
- Astrazeneca UK Limited$235K
- Novartis$208K
- Eli Lilly$78K
- GSK$73K
- Amgen$3K
- plus $4K from 17 others
Across 3 payments — averaging $351.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 333 | $909,946 |
| Astrazeneca UK Limited | 12 | $235,337 |
| Novartis | 28 | $208,196 |
| Eli Lilly | 10 | $78,213 |
| GSK | 28 | $72,531 |
| Amgen(2 entities) | 138 | $2,894 |
| Pfizer | 87 | $865 |
| E.r. Squibb & Sons, L.L.C. | 10 | $677 |
| UCB, Inc. | 34 | $521 |
| AstraZeneca(2 entities) | 25 | $464 |
| Johnson & Johnson(2 entities) | 18 | $287 |
| Radius Health, Inc. | 12 | $247 |
| Aurinia Pharma U.S., Inc. | 8 | $175 |
| Boehringer Ingelheim | 4 | $90 |
| Mallinckrodt Enterprises LLC | 3 | $83 |
| Fresenius Kabi USA, LLC | 4 | $75 |
| Bristol Myers Squibb | 5 | $64 |
| Genentech USA, Inc. | 4 | $61 |
| Sanofi | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Organon | 1 | $24 |
| Sandoz | 1 | $21 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,510,862 in reported general payments places this provider in the 95th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Las Cruces
- Chinenye OsuorjiLas Cruces$112
- Hillary NortonSanta Fe$5.1M
- Leroy PachecoAlbuquerque$2.4M
- Wilmer SibbittAlbuquerque$46K
- Ahmad RamahiRoswell$35K
- Adrian Michaella Mesilla$16K
- Albert RizzoliAlbuquerque$7K
- Susan BarrettSanta Fe$7K
- Jayashree SinhaClovis$7K
- Scott StoernerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.